513 Dynamic change of PD-L1 expression in cutaneous angiosarcoma

Positive PD-L1 Expression Predicts Worse Outcome in Cutaneous Angiosarcoma

PURPOSE Programmed death-1 (PD-1) or programmed death ligand-1 (PD-L1) targeted therapies have shown promising survival outcomes in several human neoplasms. However, it is unclear whether the expression of PD-L1 can be correlated to any clinical and pathologic variables in patients with cutaneous angiosarcoma (CA). The aim of this study was to evaluate the clinicopathological significance of PD...

Programmed Death Ligand 1 (PD-L1) Expression in Primary Angiosarcoma

Angiosarcomas are rare malignant endothelial-cell tumors of vascular or lymphatic origin, and are among the most aggressive subtypes of soft-tissue sarcomas. The prognosis is poor and treatment is challenging in many cases. PD-1/PD-L1 pathway plays a critical role in immune escape of tumor cells. Recent studies described that PD-L1 is widely expressed in various types of cancer, providing the b...

Over-Expression of Immunosuppressive Molecules, PD-L1 and PD-L2, in Ulcerative Colitis Patients

CD274 (PD-L1)-Expression in colorectal cancer

OPEN ACCESS This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http:// creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact reprin...

Cell-specific PD-L1 expression in DLBCL.

In this issue of Blood, a new study by Kiyasu et al used a double-staining technique to identify cell-specific programmed cell death ligand 1 (PD-L1) expression in 1253 diffuse large B-cell lymphoma (DLBCL) samples and analyzed the findings together with programmed death-1 (PD-1) expression in tumorinfiltrating lymphocytes (TILs) and clinical outcomes, providing new insights into the role of th...